Sarcoma  >>  Proleukin (aldesleukin)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
NCT00101309: Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma

Unknown status
1
10
US
aldesleukin, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, therapeutic autologous lymphocytes
Milton S. Hershey Medical Center
Neuroblastoma, Sarcoma
11/07
 
NCT01082926: Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

Completed
1
6
US
therapeutic allogeneic lymphocytes, ALLOLYMPH, aldesleukin, IL-2, interleukin II, Proleukin, recombinant human interleukin-2, recombinant interleukin-2, TCGF, interleukin, laboratory biomarker analysis, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed
City of Hope Medical Center
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Ependymoblastoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Grade III Meningioma, Meningeal Hemangiopericytoma, Mixed Glioma, Pineal Gland Astrocytoma, Brain Tumor
09/13
09/13
NCT03056599: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Completed
1
23
US
Multiple drug microinjection, Doxorubicin, Docetaxel, Gemcitabine, Interferon gamma, Pembrolizumab, Ipilimumab, Interferon alfa-2B, Bortezomib, Aldesleukin, Trabectedin, Eribulin, Olaratumab, Atezolizumab, Durvalumab, Avelumab, Nivolumab, Larotrectinib, Entrectinib, Avapritinib, Saline, CIVO device
Presage Biosciences, Fred Hutchinson Cancer Center, University of Washington, Northwell Health, Oregon Health and Science University
Soft Tissue Sarcoma Adult
07/21
09/21
NCI-2018-00926, NCT03450122: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Checkmark Initiation of pivotal monotherapy trial
Mar 2018 - Mar 2018: Initiation of pivotal monotherapy trial
Completed
1
15
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dendritic Cell-targeting Lentiviral Vector ID-LV305, DCvex-NY-ESO-1, ID-LV305
M.D. Anderson Cancer Center
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma
12/22
12/22
NYESO SCT, NCT03240861: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated
1
5
US
18F-FHBG, Reporter Probe 18F-FHBG, Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cellular Therapy, Cell Therapy, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT SCAN, tomography, Filgrastim, Filgrastim XM02, Filgrastim-sndz, G-CSF, Granix, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Zarxio, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
Jonsson Comprehensive Cancer Center, California Institute for Regenerative Medicine (CIRM)
HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
10/23
10/23
NCT01590069: Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Active, not recruiting
1
70
US
Aerosolized Aldesleukin, Aerosolized Recombinant IL-2, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
04/26
04/26

Download Options